# ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma

> **NCT00003989** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 50 (estimated)

## Conditions studied

- Lung Cancer
- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** ISIS 3521

## Key facts

- **NCT ID:** NCT00003989
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2012-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003989, "ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*